PRT3645
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
Trial Timeline
Dec 27, 2022 → Jun 26, 2024
NCT ID
NCT05538572About PRT3645
PRT3645 is a phase 1 stage product being developed by Prelude Therapeutics for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05538572. Target conditions include Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05538572 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer